Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2,847.0% in the 1st quarter, Holdings Channel reports. The institutional investor owned 377,213 shares of the specialty pharmaceutical company’s stock after buying an additional 364,413 shares during the period. SG Americas Securities LLC’s holdings in Supernus Pharmaceuticals were worth $19,498,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SUPN. Jefferies Financial Group Inc. grew its holdings in shares of Supernus Pharmaceuticals by 62.0% in the third quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company’s stock valued at $4,118,000 after purchasing an additional 32,979 shares during the period. Tudor Investment Corp ET AL purchased a new position in Supernus Pharmaceuticals during the third quarter worth about $1,434,000. Phocas Financial Corp. acquired a new position in Supernus Pharmaceuticals in the 4th quarter valued at about $4,042,000. Westover Capital Advisors LLC acquired a new position in Supernus Pharmaceuticals in the 4th quarter valued at about $1,587,000. Finally, Aberdeen Group plc purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $13,497,000.

Analysts Set New Price Targets

SUPN has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Trading Down 0.9%

Shares of NASDAQ:SUPN opened at $44.75 on Friday. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -87.75, a PEG ratio of 0.96 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a 12-month low of $30.93 and a 12-month high of $59.68. The business has a 50-day moving average price of $47.53 and a 200 day moving average price of $49.49.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.